肿瘤预防与治疗2026，Vol.39Issue(1)：1-4,4.DOI:10.3969/j.issn.1674-0904.2026.01.001
《CD19 CAR-T治疗成人B细胞非霍奇金淋巴瘤管理实践专家共识(2025版)》解读
Interpretation of Expert Consensus on the Management Practice of CD19 CAR-T Cell Therapy for B-Cell Lymphoma in China(2025 Edition)
摘要
Abstract
CD19 chimeric antigen receptor T-cell(CAR-T)therapy has emerged as one of the most transformative thera-pies for patients with relapsed/refractory(r/r)B-cell non-Hodgkin lymphoma(B-NHL).With multiple CD19 CAR-T prod-ucts approved in China and increasingly adopted in real-world clinical practice,the standardization of patient selection,opti-mization of treatment pathways,and maximization of both efficacy and safety have become major challenges in contemporary clinical care.In this context,the Lymphoma Expert Committee of National Cancer Quality Control Center issued the Expert Consensus on the Management Practice of CD19 CAR-T Cell Therapy for B-Cell Lymphoma in China(2025 Edition),which provides a systematic framework for the full-process management of CAR-T therapy.Integrating the latest evidence-based medical data with the Chinese clinical practice setting,this article offers a structured interpretation of the key recommenda-tions outlined in the consensus,with the aim of promoting the standardized and high-quality implementation of CAR-T thera-py for B-NHL in China.关键词
B细胞非霍奇金淋巴瘤/嵌合抗原受体T细胞/指南解读Key words
B-cell non-Hodgkin lymphoma/Chimeric antigen receptor T-cell therapy/Guideline interpretation分类
医药卫生引用本文复制引用
翁华伟,范加维,林桐榆..《CD19 CAR-T治疗成人B细胞非霍奇金淋巴瘤管理实践专家共识(2025版)》解读[J].肿瘤预防与治疗,2026,39(1):1-4,4.基金项目
国家自然科学基金区域创新发展联合基金重点项目(编号:U24A20679) （编号:U24A20679）
国家自然科学基金面上项目(编号:82470237) This study was supported by National Natural Science Foundation of China(No.U24A20679,No.82470237). （编号:82470237）
